A Phase I Dose-Escalation Study of Antibody BI-505 in Relapsed/Refractory Multiple Myeloma
| Autor: | Markus Hansson, Titti Martinsson Niskanen, Guido Tricot, Morten Mau-Sørensen, Morten Salomo, Ashraf Badros, Annika Sundberg, Fritz Offner, Peter Gimsing, Yvonne Stenberg, Stina Wichert, Björn Frendéus, Elisabeth Sonesson, Maurizio Zangari, Magnus Korsgren, Ingrid Teige, Hareth Nahi, Martine Poelman, Jan Van Droogenbroeck |
|---|---|
| Rok vydání: | 2015 |
| Předmět: |
Male
Cancer Research medicine.medical_specialty Antineoplastic Agents Gastroenterology Siltuximab chemistry.chemical_compound Recurrence Internal medicine medicine Humans Elotuzumab Adverse effect Multiple myeloma Aged Bortezomib business.industry Antibodies Monoclonal Middle Aged medicine.disease Surgery Treatment Outcome Oncology Tolerability chemistry Pharmacodynamics Female Premedication Drug Monitoring Multiple Myeloma business medicine.drug |
| Zdroj: | Clinical Cancer Research. 21:2730-2736 |
| ISSN: | 1557-3265 1078-0432 |
| DOI: | 10.1158/1078-0432.ccr-14-3090 |
| Popis: | Purpose: This multicenter, first-in-human study evaluated safety, tolerability, pharmacokinetics, and pharmacodynamics of BI-505, a human anti-ICAM-1 monoclonal antibody, in advanced relapsed/refractory multiple myeloma patients. Experimental Design: BI-505 was given intravenously, every 2 weeks, at escalating doses from 0.0004 to 20 mg/kg, with extension of therapy until disease progression for responding or stable patients receiving 0.09 mg/kg or higher doses. Results: A total of 35 patients were enrolled. The most common adverse events were fatigue, pyrexia, headache, and nausea. Adverse events were generally mild to moderate, and those attributed to study medication were mostly limited to the first dose and manageable with premedication and slower infusion. No maximum tolerated dose was identified. BI-505′s half-life increased with dose while clearance decreased, suggesting target-mediated clearance. The ICAM-1 epitopes on patient bone marrow myeloma were completely saturated at 10 mg/kg doses. Using the International Myeloma Working Group criteria, 7 patients on extended therapy had stable disease for more than 2 months. Conclusions: BI-505 can be safely administered at doses that saturate myeloma cell ICAM-1 receptors in patients. This study was registered at www.clinicaltrials.gov (NCT01025206). Clin Cancer Res; 21(12); 2730–6. ©2015 AACR. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|